iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
136 hedge funds and large institutions have $377M invested in iTeos Therapeutics in 2025 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 57 increasing their positions, 30 reducing their positions, and 35 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
90% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 30
71% more capital invested
Capital invested by funds: $221M → $377M (+$156M)
14% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 35
4% more funds holding
Funds holding: 131 → 136 (+5)
2% more ownership
Funds ownership: 96.8% → 98.8% (+2%)
3% less call options, than puts
Call options by funds: $8.46M | Put options by funds: $8.73M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$86.1M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$9.16M |
| 3 |
BCM
Boxer Capital Management
San Diego,
California
|
+$6.65M |
| 4 |
O
OrbiMed
New York
|
+$5.64M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$21.8M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$18.4M |
| 3 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$16.4M |
| 4 |
JP Morgan Chase
New York
|
-$11.1M |
| 5 |
6CM
683 Capital Management
New York
|
-$10.4M |
ITOS Hedge Fund Activity: Q2 2025 in Review
136 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q2 2025, worth a combined $377M — up 71% from $221M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new ITOS positions and 35 closed out — a net gain of 5 holders — while 57 added to existing stakes and 30 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $86.1M. The largest seller was RA Capital Management, exiting entirely with an estimated $21.8M sold.
- 136 institutional investors held iTeos Therapeutics (ITOS) as of Q2 2025, up from 131 in Q1 2025.
- Funds reported $377M of iTeos Therapeutics stock for Q2 2025, up 71% quarter-over-quarter.
- 40 funds opened new iTeos Therapeutics positions in Q2 2025 and 35 closed out, a net change of +5 holders.
- The largest iTeos Therapeutics buyer in Q2 2025 was EcoR1 Capital, an estimated $86.1M added.
- The largest iTeos Therapeutics seller in Q2 2025 was RA Capital Management, an estimated $21.8M sold.
Based on aggregated 13F filings for Q2 2025.